Codexis, Inc. (CDXS) Insider Trading Activity

NASDAQ$1.0788
Market Cap
$118.27M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
470 of 849
Rank in Industry
272 of 491

CDXS Insider Trading Activity

CDXS Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$4,889,111
17
100

Related Transactions

De Vre Raymonddirector
0
$0
2
$8,632
$-8,632
Erbez GeorgiaSee Remarks
0
$0
2
$13,620
$-13,620
MOORE ALISONPresident and CEO
0
$0
2
$13,620
$-13,620
WOLF DENNIS Pdirector
0
$0
1
$13,988
$-13,988
Lutz StefanCSO
0
$0
3
$17,848
$-17,848
Opaleye Management Inc.10 percent owner
0
$0
7
$4.82M
$-4.82M

About Codexis, Inc.

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its …

Insider Activity of Codexis, Inc.

Over the last 12 months, insiders at Codexis, Inc. have bought $0 and sold $4.89M worth of Codexis, Inc. stock.

On average, over the past 5 years, insiders at Codexis, Inc. have bought $4.63M and sold $2.44M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 780 shares for transaction amount of $2,211 was made by Opaleye Management Inc. (10 percent owner) on 2025‑08‑04.

List of Insider Buy and Sell Transactions, Codexis, Inc.

2026-10-12SaleMOORE ALISONPresident and CEO
6,335
0.0067%
$1.36
$8,619
-9.22%
2026-10-12SaleErbez GeorgiaSee Remarks
6,335
0.0067%
$1.36
$8,619
-9.22%
2026-06-11SaleDe Vre Raymonddirector
2,605
0.0029%
$2.37
$6,174
-38.59%
2026-02-24SaleLutz StefanChief Scientific Officer
5,862
0.0067%
$1.13
$6,641
+49.55%
2026-02-06SaleMOORE ALISONPresident and CEO
3,826
0.0042%
$1.31
$5,001
+20.30%
2026-02-06SaleLutz StefanChief Scientific Officer
2,492
0.0027%
$1.31
$3,257
+20.30%
2026-02-06SaleErbez GeorgiaSee Remarks
3,826
0.0042%
$1.31
$5,001
+20.30%
2026-01-07SaleLutz StefanCSO
4,685
0.0055%
$1.70
$7,950
-5.88%
2025-12-01SaleOpaleye Management Inc.10 percent owner
253,533
0.3021%
$1.67
$422,766
-0.61%
2025-11-28SaleOpaleye Management Inc.10 percent owner
107,490
0.1282%
$1.75
$188,108
-5.20%
2025-11-26SaleOpaleye Management Inc.10 percent owner
148,318
0.175%
$1.74
$258,266
-5.75%
2025-11-21SaleWOLF DENNIS Pdirector
8,952
0.0107%
$1.56
$13,988
+6.49%
2025-11-12SaleOpaleye Management Inc.10 percent owner
1.08M
1.4656%
$1.94
$2.1M
-15.03%
2025-11-11SaleOpaleye Management Inc.10 percent owner
548,211
0.6881%
$1.80
$986,451
-8.89%
2025-11-11SaleDe Vre Raymonddirector
1,413
0.0017%
$1.74
$2,459
-8.89%
2025-11-10SaleOpaleye Management Inc.10 percent owner
208,318
0.2521%
$1.73
$361,369
-6.29%
2025-11-07SaleOpaleye Management Inc.10 percent owner
296,682
0.2646%
$1.70
$503,410
-2.96%
2025-10-13SaleMOORE ALISONChief Technical Officer
6,239
0.0078%
$2.51
$15,629
-32.80%
2025-10-13SaleErbez GeorgiaChief Financial Officer
6,239
0.0078%
$2.50
$15,629
-32.80%
2025-08-04PurchaseOpaleye Management Inc.10 percent owner
780
0.001%
$2.83
$2,211
-20.42%
Total: 257
*Gray background shows transactions not older than one year

Insider Historical Profitability

1.48%
Opaleye Management Inc.10 percent owner
179989
0.1644%
$194,388.12427
<0.0001%
NICOLS JOHN Jdirector
783965
0.7159%
$846,682.20431
<0.0001%
DILLY STEPHEN GEORGESee Remarks
438878
0.4008%
$473,988.2412
+69.19%
SHAW ALANPresident and CEO
202000
0.1845%
$218,160.00112
+25.75%
Ryali SriramChief Financial Officer
123441
0.1127%
$133,316.2810
+69.19%
O'Toole David DSVP & Chief Financial Officer
115384
0.1054%
$124,614.7240
<0.0001%
Norrett KevinChief Operating Officer
98102
0.0896%
$105,950.1612
+65.06%
Fitzgerald Margaret NellSee Remarks
81420
0.0744%
$87,933.6012
+69.19%
Anton David L.SVP, BioIndustrials
70200
0.0641%
$75,816.0011
+25.75%
Sheehy Douglas T.SVP, General Counsel & Sec.
69200
0.0632%
$74,736.0011
+25.75%
Lawson Robert JSVP and CFO
44000
0.0402%
$47,520.0020
<0.0001%
Yang Patrick Y
42512
0.0388%
$45,912.961212
+15.01%
BARUCH THOMAS Rdirector
33093
0.0302%
$35,740.44115
+28.81%
Pasternack Bruce Adirector
10000
0.0091%
$10,800.0030
+29.98%
Sarret Joseph J.CBO, President Pharmaceuticals
2000
0.0018%
$2,160.0010
+25.75%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

Codexis, Inc.
(CDXS)
$16,280,851
76
1.48%
$118.27M
$4,898,715
46
40.75%
$114.69M
$130,095
43
45.19%
$111.24M
$6,788,859
35
26.72%
$151.54M
$47,438,336
33
-21.38%
$122.37M

CDXS Institutional Investors: Active Positions

Increased Positions67+49.63%12M+18.92%
Decreased Positions55-40.74%13M-20.42%
New Positions16New1MNew
Sold Out Positions22Sold Out5MSold Out
Total Postitions147+8.89%65M-1.49%

CDXS Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Opaleye Management Inc.$20,600.0014.22%12.79M+195,000+1.55%2025-09-30
Blackrock, Inc.$11,502.007.94%7.14M+8,010+0.11%2025-09-30
Vanguard Group Inc$7,518.005.19%4.67M+80,602+1.76%2025-09-30
Aberdeen Group Plc$6,588.004.55%4.09M-108,888-2.59%2025-09-30
Millennium Management Llc$6,549.004.52%4.07M+4M+3,376.49%2025-09-30
Nantahala Capital Management, Llc$6,489.004.48%4.03M00%2025-09-30
Telemark Asset Management, Llc$6,440.004.44%4M00%2025-09-30
Ameriprise Financial Inc$4,466.003.08%2.77M+222,840+8.74%2025-09-30
Geode Capital Management, Llc$3,208.002.21%1.99M+14,535+0.73%2025-09-30
Pier Capital, Llc$3,045.002.1%1.89M-23,928-1.25%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.